Last reviewed 2026-04-23 · How we verify

Telmisartan + Rosuvastatin

Telmisartan + Rosuvastatin is a Angiotensin II receptor antagonist, Statin Small molecule drug developed by Daewon Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Hypertension, Hyperlipidemia.

Telmisartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering LDL cholesterol.

Telmisartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering LDL cholesterol. Used for Hypertension, Hyperlipidemia.

At a glance

Mechanism of action

Telmisartan works by blocking the angiotensin II type 1 receptor, which is a key component of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. By blocking this receptor, telmisartan causes vasodilation and reduces blood pressure. Rosuvastatin, on the other hand, works by inhibiting the enzyme HMG-CoA reductase, which is a key step in the biosynthesis of cholesterol. By inhibiting this enzyme, rosuvastatin reduces the production of cholesterol in the liver and increases the clearance of LDL cholesterol from the bloodstream.

Approved indications

• Hypertension, Hyperlipidemia

Common side effects

• Cough
• Dizziness
• Headache
• Muscle pain
• Nausea

Key clinical trials

• To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome (NA)
• High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension (PHASE4)
• Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine (PHASE3)
• Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension (PHASE4)
• Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan (PHASE3)
• HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria (PHASE4)
• To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia (PHASE3)
• The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Telmisartan + Rosuvastatin CI brief — competitive landscape report
• Telmisartan + Rosuvastatin updates RSS · CI watch RSS
• Daewon Pharmaceutical Co., Ltd. portfolio CI

Frequently asked questions about Telmisartan + Rosuvastatin

Related

• Drug class: All Angiotensin II receptor antagonist, Statin drugs
• Target: All drugs targeting AT1 receptor, HMG-CoA reductase
• Manufacturer: Daewon Pharmaceutical Co., Ltd. — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Hypertension, Hyperlipidemia
• Compare: Telmisartan + Rosuvastatin vs similar drugs
• Pricing: Telmisartan + Rosuvastatin cost, discount & access